miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 4, 2026

Ladder Capital's Asset Management Head Sells 35,000 Shares — What's Really at Stake?

View original at finance.yahoo.com
Ladder Capital's Asset Management Head Sells 35,000 Shares — What's Really at Stake? On May 29 and June 2, 2026, Robert Perelman, Head of Asset Management at Ladder Capital Corp (NYSE:LADR), reported the open-market sale of 35,000 shares of Common Stock, according to a SEC Form 4 filing…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Over the past two years, Perelman executed two open-market sales totaling 60,000 shares; the 35,000-share transaction is his largest individual direct sale in that period, with the prior sale involving 25,000 shares.

    60% confidence
  • This transaction accounted for 7.55% of Perelman's direct Common Stock position, reducing his direct holdings from 463,684 to 428,684 shares.

    60% confidence
  • Perelman continues to hold 428,684 shares of Common Stock directly, supporting a continuing alignment with shareholders.

    60% confidence
  • No indirect holdings or derivative securities were involved; all shares sold were held directly, with no involvement from trusts, LLCs, or derivative securities.

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Ladder Capital's Asset Management Head Sells 35,000 Shares — What's Really at Stake? — Source | Via News | es.VIA.NEWS